This Italian paper demonstrates that a skin biopsy has good diagnostic value in PD. In clinical studies, this could be one possibility to see a treatment effect, whenever 434 will be tested in the PD population.

Brain

. 2025 Sep 8:awaf313.

doi: 10.1093/brain/awaf313. Online ahead of print.

Skin intraneural phosphorylated α-synuclein is a highly specific biomarker for early Parkinson's disease

Vincenzo Donadio ^{1 2}, Alex Incensi ¹, Giovanni Rizzo ¹, Allessandro Furia ^{1 2}, Salvatore Bonvenga ³, Enrica Olivola ⁴, Marco Piatti ^{3 5}, Francesco Ventruto ¹, Veria Vacchiano ¹, Cecilia Delprete ¹, Martin Ingelsson ^{6 7 8 9 10}, Nicola Modugno ⁴, Ronald Postuma ¹¹, Roberto Cilia ¹², Rocco Liguori ^{1 2}

Affiliations Expand

• PMID: 40920014

DOI: 10.1093/brain/awaf313

Abstract

An early diagnosis of Parkinson's disease (PD) represents a challenge and novel accurate biomarkers are therefore urgently needed. Detection of phosphorylated α-synuclein (p-α-syn) in skin nerve fibers has shown promise as such a marker. However, its accuracy for the identification of PD among patients with early signs of parkinsonism has not been thoroughly explored. In this blinded, multicenter, prospective and follow-up study, 151 patients diagnosed with early-stage parkinsonism (<18 months duration) were enrolled at three tertiary movement disorders centers. Clinical scales were performed and initial diagnoses were reassessed at 18 and 46 months follow-up visits. Skin biopsy, with analysis for neuronal and glial p-α-syn deposits, and olfactory testing were performed at the baseline visit and repeated in 44 patients at the 18 months visit. After the follow-up period, a final diagnosis was reached in 140 patients: PD (n=101; 67% of all screened patients), tauopathies (n=22; 15%), multiple system atrophy (n=5; 3%), vascular parkinsonism (n=4; 3%), essential tremor (n=3; 2%), dystonic tremor (n=2; 1%) and no neurological illness (n=3, 2%). Eleven patients did not fit any clinical criteria and were therefore classified as undefined. Baseline skin intraneural p-α-syn showed a robust diagnostic accuracy (81% sensitivity and 100% specificity) for identifying PD. Importantly, in 30 out of 44 patients not diagnosed with PD until the follow-up intraneural p-α-syn was positive already at baseline. Moreover, the analyses showed a large degree of consistency over time, as the same results at baseline and follow-up were obtained in 42 (96%) of the tested patients. Finally, although olfactory testing at baseline showed a more abnormal score in PD compared to the other groups, its predictive accuracy was more modest (72%). In conclusion, given its high sensitivity, specificity and reproducibility, skin intraneural p-α-syn could become a valuable tool for diagnosing PD at early stages, potentially years before the diagnostic criteria are met, and for differentiating PD from atypical parkinsonism. In contrast, olfactory function, although more impaired in PD than in non-PD patients, only seems to have a more limited diagnostic accuracy.